Nkarta, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Nkarta, Inc. (NKTX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$40.16 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-17.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2022-03-17
- Nkarta, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2020-12-31 was $0.00.
- Nkarta, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Nkarta, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2020-06-30 was -$40.74M.
- Nkarta, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2020-03-31 was $578.00K.
- Nkarta, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2020 was -$40.16M, a 3147.27% decline from fiscal 2019.
- Nkarta, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2019 was $1.32M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | -$40.74M derived: sum of 3 quarters · filed 2022-03-17 | -$40.16M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$40.74M derived: sum of 2 quarters · filed 2021-11-10 | -$40.16M 10-Q · filed 2021-11-10 | -$42.23M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | -$40.74M 10-Q · filed 2021-08-12 | -$40.16M 10-Q · filed 2021-08-12 | -$40.16M 10-Q · filed 2020-08-20 | -$42.23M derived: sum of 3 quarters · filed 2021-08-12 | -$38.84M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $578.00K 10-Q · filed 2021-05-13 | -$1.49M derived: sum of 2 quarters · filed 2021-05-13 | $1.90M derived: sum of 3 quarters · filed 2021-05-13 | ||
| 2019-12-31 | -$2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.32M derived: sum of 2 quarters · filed 2021-03-25 | $1.32M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $3.38M 10-Q · filed 2020-11-12 | $3.38M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |